千金药业(600479.SH)：盐酸鲁拉西酮片获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the psychiatric medication market [1] Group 1: Company Developments - The approval of Lurasidone Hydrochloride Tablets is aimed at treating schizophrenia, which broadens the therapeutic options available to patients [1] - The drug was originally developed by Sunovion Pharmaceuticals Inc. and was first launched in the United States in October 2010, with domestic import approval granted in January 2019 [1] - Other companies that have received registration for this drug in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] Group 2: Market Insights - According to Morin Data, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025, indicating a growing market potential for this medication [1]